China NMPA Drug Inspection - Hainan Haishen Tongzhou Pharmaceutical Co., Ltd. - Gongyankang Granules
China NMPA drug inspection for Hainan Haishen Tongzhou Pharmaceutical Co., Ltd. published January 26, 2017. Drug: Gongyankang Granules. On January 26, 2017, China's State Administration for Market Regulation (formerly SFDA) announced findings of 14 batches
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Hainan Haishen Tongzhou Pharmaceutical Co., Ltd. published January 26, 2017. Drug: Gongyankang Granules. On January 26, 2017, China's State Administration for Market Regulation (formerly SFDA) announced findings of 14 batches
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox